Atritech, Inc. Appoints Jim Bullock as President and CEO

Atritech, Inc. Appoints Jim Bullock as President and CEO

Jul 5, 2005 – Minneapolis, MN – Atritech, Inc. (“Atritech”) announces the appointment of Jim Bullock to the position of President and Chief Executive Officer. Bullock, previously an Entrepreneur-in-Residence for Split Rock Partners, was recruited for his extensive leadership experience in bringing early stage medical device companies through product development and into commercialization.

“Jim brings the energy and leadership experience we need to continue the success of the Atritech story,” said Dave Stassen, Managing Director at Split Rock and Board member of Atritech. “The company’s WATCHMAN device has been successfully managed from concept through the completion of an international clinical feasibility trial. Now it is time to take it to the next level. Jim has the unique combination of skills and experience necessary to lead Atritech through the completion of its pivotal, U.S. clinical trial and maximize its commercial potential.”

“I am excited to have the opportunity to join the experienced team assembled at Atritech,” said Bullock. “The Watchman technology developed by the Atritech team has tremendous potential to change the way patients with atrial fibrillation are currently managed.”

Between 1994 and 2005, Bullock was President and Chief Executive Officer of St. Paul based Endocardial Solutions, Inc. (“ESI”) which develops, manufactures and markets products to diagnose and treat atrial fibrillation and other cardiac arrhythmias. During his tenure at ESI, Bullock led the company through a successful public offering, grew revenues to $50 million and presided over its acquisition by St. Jude Medical, Inc. for $273 million in January 2005. Before joining ESI, Bullock served as the President and Chief Executive Officer of Stuart Medical, Inc., a cardiac monitoring start-up company. Bullock also held a variety of senior marketing and sales management positions at Stackhouse, a division of Bird Medical Technologies and Pharmaseal, a division of Baxter International.

About Atritech
Atritech has developed the WATCHMAN left atrial appendage system, a novel device based solution to isolate the left atrial appendage in patients with atrial fibrillation who require blood thinning medications. The device is designed to capture clots that may form in the appendage potentially reducing the risk of stroke and eliminating the need for the long term use of blood thinning medications. Atritech is privately held and based in Plymouth, Minnesota. Major investors in Atritech include Split Rock Partners, The Vector Group, and Thoma Cressey Funds. For more information, visit www.atritech.net.